Desravines Nerlyne, Desjardins Michael R, Ferriss J Stuart, Perrin Jamie, Rahangdale Lisa
Division of Gynecologic Oncology, Department of Women's Health, University of Texas at Austin Dell Medical School, Austin, TX.
Department of Epidemiology and Spatial Science for Public Health Center, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD.
J Low Genit Tract Dis. 2025 Jul 1;29(3):243-250. doi: 10.1097/LGT.0000000000000880. Epub 2025 Mar 18.
To estimate the proportion of participants with high-grade cervical intraepithelial neoplasia (CIN 2/3) who completed indicated therapeutic procedures.
This was a retrospective observational cohort study of the National Institutes of Health's All of Us database enriched for racial and ethnic minorities historically underrepresented in biomedical research. The study included female participants aged 25 and older with a diagnosis of CIN 2/3 only, excluding invasive malignancy. The authors conducted both univariate and multivariate logistic regression to identify background characteristics associated with guideline-concordant ablative and excisional procedures.
Of 1,764 participants with CIN 2/3, only 27.7% of participants underwent a therapeutic procedure in the 12 months following a diagnosis of CIN 2/3. The study found that Hispanic participants had a 1.48 increased odds ratio (OR) (95% CI = 1.18-1.85) of undergoing therapeutic procedures (compared to non-Hispanic). Participants residing in the Midwest had a 2.04 OR (95% CI = 1.6-2.6) of undergoing a therapeutic procedure compared to the Northeast. After adjustment for race, ethnicity, region, and smoking status, Hispanic ethnicity remained associated with therapeutic excision (OR = 2.37, 1.13-4.78). Geography was significant with 2.37 (95% CI = 1.17-3.29) increased odds of therapy completions for Midwest residents but 0.52 (95% CI = 0.27-0.96) decreased odds for Western residents.
In this large US national database enriched for racial and ethnic minorities, the authors found that 3 of 4 participants with cervical precancer did not undergo a therapeutic procedure in the 12 months following their first diagnosis. Increased efforts to promote access to and completion of treatment of CIN 2/3 are needed to prevent cancer.
评估完成指定治疗程序的高级别宫颈上皮内瘤变(CIN 2/3)参与者的比例。
这是一项对美国国立卫生研究院“我们所有人”数据库进行的回顾性观察队列研究,该数据库纳入了生物医学研究中历史上代表性不足的少数族裔。该研究纳入了年龄在25岁及以上、仅诊断为CIN 2/3且排除浸润性恶性肿瘤的女性参与者。作者进行了单变量和多变量逻辑回归分析,以确定与符合指南的消融和切除手术相关的背景特征。
在1764名CIN 2/3参与者中,只有27.7%的参与者在被诊断为CIN 2/3后的12个月内接受了治疗程序。研究发现,西班牙裔参与者接受治疗程序的优势比(OR)增加了1.48(95%CI = 1.18 - 1.85)(与非西班牙裔相比)。与东北部相比,居住在中西部的参与者接受治疗程序的OR为2.04(95%CI = 1.6 - 2.6)。在对种族、民族、地区和吸烟状况进行调整后,西班牙裔仍然与治疗性切除相关(OR = 2.37,1.13 - 4.78)。地理位置具有显著影响,中西部居民完成治疗的优势比增加2.37(95%CI = 1.17 - 3.29),而西部居民则降低0.52(95%CI = 0.27 - 0.96)。
在这个纳入了少数族裔的大型美国国家数据库中,作者发现四分之三的宫颈癌前病变参与者在首次诊断后的12个月内未接受治疗程序。需要加大力度促进CIN 2/3治疗的可及性和完成率,以预防癌症。